| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-06-3964 |
| P8608 | Fatcat ID | release_cxgqpocd6vdyfeuafthxiwesxy |
| P698 | PubMed publication ID | 17234790 |
| P50 | author | Paul Dent | Q73523499 |
| P2093 | author name string | Shuang Chen | |
| Steven Grant | |||
| Yun Dai | |||
| Hisashi Harada | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 782-791 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | |
| P478 | volume | 67 |
| Q92565328 | 3-Chloroplumbagin Induces Cell Death in Breast Cancer Cells Through MAPK-Mediated Mcl-1 Inhibition |
| Q33662495 | 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation |
| Q37670967 | A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition |
| Q52822011 | A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight. |
| Q33843635 | A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions. |
| Q89863923 | A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-P53 inhibitor in Diffuse Large B-Cell Lymphoma |
| Q27649579 | A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation |
| Q39700222 | A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. |
| Q40007589 | A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. |
| Q34241381 | A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo |
| Q33833506 | A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy |
| Q39965483 | ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis |
| Q34144923 | ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. |
| Q36425600 | ABT-737 synergizes with Bortezomib to kill melanoma cells |
| Q39280369 | ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo |
| Q39879308 | ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway |
| Q39025514 | ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines |
| Q42094231 | ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells |
| Q39697805 | ARC synergizes with ABT-737 to induce apoptosis in human cancer cells |
| Q33806087 | Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. |
| Q39664189 | Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines |
| Q39659332 | Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression |
| Q37034852 | Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival |
| Q39525276 | Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. |
| Q28084243 | Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells |
| Q34685438 | Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms |
| Q35266213 | An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. |
| Q36482941 | Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis |
| Q26862539 | Anti-apoptotic BCL-2 family proteins in acute neural injury |
| Q52571263 | Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. |
| Q38909188 | Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines |
| Q37410515 | Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. |
| Q37828794 | Apoptosis and oncogenesis: give and take in the BCL-2 family |
| Q39956386 | Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins |
| Q27016160 | Apoptotic agents |
| Q36905328 | Apoptotic effect of hot water extract of Sanguisorba officinalis L. in human oral cancer cells |
| Q36057706 | Artesunate induces ROS-dependent apoptosis via a Bax-mediated intrinsic pathway in Huh-7 and Hep3B cells |
| Q35688720 | Artesunate induces apoptosis via a ROS-independent and Bax-mediated intrinsic pathway in HepG2 cells |
| Q35212727 | Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. |
| Q36813008 | BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins |
| Q34891196 | BCL-2 family antagonists for cancer therapy |
| Q37268123 | BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing |
| Q36935301 | BCL-2 family regulation by the 20S proteasome inhibitor bortezomib |
| Q37235693 | BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells |
| Q39920726 | BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. |
| Q40122807 | BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. |
| Q34168023 | BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells |
| Q41694352 | BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells |
| Q24655483 | BH3 mimetics to improve cancer therapy; mechanisms and examples |
| Q36948615 | BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists |
| Q36658048 | BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma |
| Q26823996 | Bcl-2 antagonists: a proof of concept for CLL therapy |
| Q37275477 | Bcl-2 inhibitors: small molecules with a big impact on cancer therapy |
| Q39300586 | Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. |
| Q40053598 | Bcl-2 modulation to activate apoptosis in prostate cancer |
| Q38825797 | Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding |
| Q36880621 | Bcl-2-regulated apoptosis: mechanism and therapeutic potential |
| Q30495553 | Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization |
| Q37451892 | Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. |
| Q39885694 | Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis |
| Q90412228 | By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737 |
| Q27670943 | CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells |
| Q36170136 | CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies |
| Q92992525 | CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax |
| Q38704051 | CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. |
| Q29616694 | Cancer drug resistance: an evolving paradigm |
| Q38982534 | Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. |
| Q24315549 | Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency |
| Q36853190 | Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells |
| Q37713757 | Chemosensitization of prostate cancer by modulating Bcl-2 family proteins |
| Q36980678 | Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer |
| Q28540339 | Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells |
| Q33830911 | Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics |
| Q50784260 | Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation. |
| Q38964512 | Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines |
| Q36337587 | Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. |
| Q36544778 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia |
| Q55070853 | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. |
| Q34344158 | Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types |
| Q34683589 | Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect |
| Q54472192 | Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia? |
| Q37725409 | Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells |
| Q27652276 | Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim |
| Q37114045 | Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells |
| Q27657282 | Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands |
| Q43127379 | Coordinate PI3K pathway and Bcl-2 family disruption in AML. |
| Q40093022 | Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. |
| Q36015334 | Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy |
| Q24561485 | Cyclin-dependent kinase inhibitor therapy for hematologic malignancies |
| Q36447801 | DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites |
| Q51311600 | DMFC (3,5-dimethyl-7H-furo[3,2-g]chromen-7-one) regulates Bim to trigger Bax and Bak activation to suppress drug-resistant human hepatoma. |
| Q49374158 | DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a |
| Q36629141 | Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737 |
| Q33839850 | Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. |
| Q37059647 | Diagnosing and exploiting cancer's addiction to blocks in apoptosis |
| Q35620926 | Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells |
| Q35846538 | Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines |
| Q35880102 | Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation |
| Q35153790 | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells |
| Q39741953 | Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy |
| Q37786022 | Drugs targeting Bcl-2 family members as an emerging strategy in cancer |
| Q88619003 | Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition |
| Q36625664 | Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. |
| Q38901662 | EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma |
| Q35419363 | ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1 |
| Q35550064 | ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer |
| Q46866934 | Effect of HA14-1 on apoptosis-regulating proteins in HeLa cells |
| Q90448064 | Effects of ABT-737 combined with irradiation treatment on uterine cervical cancer cells |
| Q33682689 | Emerging Bcl-2 inhibitors for the treatment of cancer |
| Q35975127 | Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy |
| Q37124747 | Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents |
| Q38891118 | Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter |
| Q46640442 | Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo |
| Q92172753 | Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancer |
| Q90654803 | Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737 |
| Q27355520 | Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer |
| Q64115883 | Global Gene Networks in 3D4/31 Porcine Alveolar Macrophages Treated with Antigenic Epitopes of Actinobacillus pleuropneumoniae ApxIA, IIA, and IVA |
| Q33425096 | HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression |
| Q24305060 | Heterodimerization of BAK and MCL-1 activated by detergent micelles |
| Q37317447 | High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition |
| Q92962230 | Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine |
| Q39577806 | Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. |
| Q37705988 | Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells |
| Q54990441 | Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. |
| Q36970689 | In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas |
| Q34167974 | Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. |
| Q36931453 | Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma |
| Q33750838 | Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells |
| Q58553038 | Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx strategies through Mcl-1 down-regulation |
| Q36541458 | Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review |
| Q37337409 | Is the focus moving toward a combination of targeted drugs? |
| Q35579660 | JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. |
| Q36952270 | Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation |
| Q38040353 | MAP kinase signaling and inhibition in melanoma |
| Q94553947 | MCL-1Matrix maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions |
| Q36706340 | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex |
| Q35990714 | MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism |
| Q36751575 | MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. |
| Q41839159 | MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family |
| Q33989964 | Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression |
| Q37104378 | Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). |
| Q24312998 | Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines |
| Q35209685 | Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine |
| Q37187536 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia |
| Q34912378 | Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. |
| Q37566211 | Mimicking the BH3 domain to kill cancer cells |
| Q28069552 | Mitochondrial apoptosis and BH3 mimetics |
| Q37694737 | Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified |
| Q37688278 | Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival |
| Q92953592 | Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo |
| Q33920494 | New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer |
| Q39929571 | Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms |
| Q38828546 | Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells |
| Q35075657 | OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis |
| Q36697045 | Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo |
| Q38212609 | Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective |
| Q34541989 | Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers |
| Q39132575 | PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis. |
| Q39108771 | PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment |
| Q39077562 | Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein |
| Q51160342 | Pathways and mechanisms of venetoclax resistance. |
| Q40070342 | Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma |
| Q34621121 | Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. |
| Q39443671 | Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. |
| Q39205781 | Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis |
| Q35543223 | Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). |
| Q42425463 | Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC. |
| Q38755091 | Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia |
| Q28534817 | Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells |
| Q30361951 | Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. |
| Q35643014 | Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells |
| Q33494047 | RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway |
| Q35750491 | Rational Combinations of Targeted Agents in AML |
| Q33840360 | Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. |
| Q42854212 | Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. |
| Q39789593 | Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L). |
| Q37132625 | Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia |
| Q50652032 | Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases. |
| Q34399676 | Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. |
| Q39787753 | Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas |
| Q34953963 | Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells |
| Q37555793 | Small molecules and targeted therapies in distant metastatic disease. |
| Q24646161 | Small-molecule Bcl-2 antagonists as targeted therapy in oncology |
| Q37799747 | Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule. |
| Q89987678 | Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1 |
| Q37531724 | Strategies for optimizing the response of cancer and normal tissues to radiation |
| Q36739519 | Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein. |
| Q37045295 | Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models |
| Q34323880 | Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma |
| Q47349096 | Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737. |
| Q35920657 | Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 |
| Q35093687 | Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines |
| Q33415723 | Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. |
| Q33851111 | Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis |
| Q27011870 | Targeting Mcl-1 for the therapy of cancer |
| Q37410635 | Targeting SOD1 reduces experimental non–small-cell lung cancer |
| Q64074806 | Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies |
| Q35150651 | Targeting mcl-1 for radiosensitization of pancreatic cancers |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q83158104 | Targeting mitochondria for cancer therapy |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q38726551 | Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia |
| Q37120213 | Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? |
| Q39575518 | Targeting the regulatory machinery of BIM for cancer therapy |
| Q36033266 | Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells |
| Q92445776 | The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death |
| Q39819844 | The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells |
| Q39466656 | The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells |
| Q33612421 | The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells |
| Q38976876 | The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic |
| Q39363181 | The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. |
| Q37331873 | The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD |
| Q34484344 | The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition |
| Q34975398 | The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters |
| Q39456653 | The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells |
| Q28487756 | The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity |
| Q34557856 | The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737 |
| Q42117299 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine |
| Q37431491 | Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics |
| Q36173303 | Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer |
| Q28484487 | Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells |
| Q33645250 | Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells |
| Q37092954 | Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. |
| Q36681060 | YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context |
| Q35474400 | miR-193b Regulates Mcl-1 in Melanoma |
| Q39457437 | p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. |
| Q40150613 | sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell |
Search more.